Showing 3731-3740 of 5660 results for "".
- MDRejuvena Launches Vivatia Skin Lightening Product Line in UShttps://practicaldermatology.com/news/mdrejuvena-launches-vivatia-skin-lightening-product-line-in-us/2458014/MDRejuvena, Inc., has launched the Vivatia skin lightening product line in the US. Vivatia incorporates a patented, proprietary foam technology that enhances the dispersion and absorption of active ingredients into the skin. Vivatia has been clinically studied and proven effective for hyperpigmen
- ASDS Honors Top Choose Skin Health Skin Cancer Screenershttps://practicaldermatology.com/news/asds-honors-top-choose-skin-health-skin-cancer-screeners/2458021/The American Society for Dermatologic Surgery (ASDS) honored the top screeners in
- FDA Adds Third Approved Indication for Botox Cosmetic: Forehead Lineshttps://practicaldermatology.com/news/fda-adds-third-approved-indication-for-botox-cosmetic-forehead-lines/2458032/Allergan plc's Botox Cosmetic received ts third FDA indication—the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults. This approval makes the brand the first and only neurotoxin indicated for three facial tre
- Lilly to Present New Data for Olumiant® and Taltz® at EADVhttps://practicaldermatology.com/news/lilly-to-present-new-data-for-olumiant-and-taltz-eadv/2458060/Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation are partners on the develo
- Link Found Between a Molecular Driver of Melanoma Progression and Novel Therapeutic Agenthttps://practicaldermatology.com/news/link-found-between-a-molecular-driver-of-melanoma-progression-and-novel-therapeutic-agent/2458065/Research linking autophagy with the Wnt signaling pathway, a key regulator of melanoma progression and metastasis, may guide effective use of autophagy inhibitors. The findings appear online in Cancer Research. Autophagy allows cancer cells to survive under stressful cond
- GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologicshttps://practicaldermatology.com/news/gbi-research-global-dermatology-pipeline-to-see-shift-toward-increased-use-of-biologics/2458071/The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of the pipeline dominated by generics and biosimilars, according to GBI Research. The company
- New Criteria Aims to Help Doctors Spot Amelanotic Melanoma Earlierhttps://practicaldermatology.com/news/new-criteria-aims-to-help-doctors-spot-amelanotic-melanoma-earlier/2458092/New research outlines key features linked to amelanotic melanoma. The findings, which appear in JAMA Dermatology, may help improve detection of this type of melanoma, which is more likely to be diagnosed at advanced stages because it falls outside of the “ABCDE” guide
- Histogen's Growth Factor Technology Now Part of Allergan's Skin Care Linehttps://practicaldermatology.com/news/histogens-growth-factor-technology-now-part-of-allergan-skin-care-line/2458111/Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System. The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors
- Tomatoes May Slash Skin Cancer Riskhttps://practicaldermatology.com/news/tomatoes-may-slash-skin-cancer-risk/2458122/Daily tomato consumption may cut skin cancer risk in half, according to a new study in mice. The Ohio State University researchers report their findings online in the journal
- FDA Clears Philips BlueControl Wearable Light Therapy Device to Treat Mild Psoriasis At Homehttps://practicaldermatology.com/news/fda-clears-philips-bluecontrol-wearable-light-therapy-device-to-treat-mild-psoriasis-at-home/2458124/The FDA has granted Royal Philips 510(k) clearance to market the Philips BlueControl wearable light therapy device to treat mild psoriasis. In the US, BlueControl is a Class II prescription medical device designed for home use. Clinical studies have demonstrated that the UV-free blue LED